[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colorectal-cancer-microsatellite-stable-mss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colorectal-cancer-microsatellite-stable-mss":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100627271",false,"NCT07446465","FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR\u002FMSS Colorectal Cancer","Exploratory Clinical Study of FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR\u002FMSS Colorectal Cancer","Inclusion Criteria:\n\n* Age 18-75 years;\n* Histologically confirmed adenocarcinoma of colorectal cancer, initially unresectable locally advanced or metastatic\u002Frecurrent disease;\n* Expected survival ≥12 weeks;\n* No prior systemic antitumor therapy for colorectal cancer;\n* Confirmed pMMR by IHC or MSS\u002FMSI-L by PCR or NGS;\n* ECOG PS 0-1;\n* At least one measurable lesion per RECIST v1.1;\n* Adequate organ and bone marrow function;\n* Controlled viral hepatitis status as specified;\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Prior immune checkpoint inhibitor therapy;\n* CNS or leptomeningeal metastases;\n* Uncontrolled cardiovascular disease or hypertension;\n* Active autoimmune disease requiring systemic therapy;\n* Active infection including tuberculosis;\n* Recent major surgery;\n* Pregnancy or lactation;\n* Any condition deemed by investigators to compromise safety or study compliance.","ALL","18 Years","75 Years",{"count":19,"type":20},42,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","To evaluate the efficacy and safety of immune checkpoint inhibitor-based combination therapy with targeted therapy and chemotherapy in patients with locally advanced unresectable or metastatic colorectal cancer.",[26,27],"Colorectal Cancer (Locally Advanced or Metastatic)","Colorectal Cancer Microsatellite Stable (MSS)","NOT_YET_RECRUITING","2026-02-28",{"date":31,"type":32},"2026-03-03","ACTUAL",{"date":34,"type":20},"2026-03-01",{"date":36,"type":20},"2027-01-31",{"name":38,"class":39},"Ye Xu","OTHER",""]